Navigation Links
Assessing the value of treatments to increase height
Date:3/31/2011

CLEVELAND -- Dr. Leona Cuttler, a pediatric endocrinologist and growth hormone expert from University Hospitals Rainbow Babies and Children's Hospital, is the co-author of an editorial in the New England Journal of Medicine commenting on a new study that found giving girls with Turner syndrome low doses of estrogen, as well as growth hormone, years before the onset of puberty, increases their height and offers other benefits.

With her co-author Dr. Robert L. Rosenfield, a pediatric endocrinologist with the University of Chicago Medical Center, Dr. Cuttler writes, "The use of growth hormone and estrogen has a long and often controversial history in the manipulation of growth."

About the new study, they write that the results confirm those of previous, less rigorous studies showing that treatment with growth hormone significantly increased adult height in patients with Turner's syndrome.

Drs. Cuttler and Rosenfield say the results suggest a modest but intriguing synergism between growth hormone and low-dose estrogen in promoting growth.

"The impact of these findings on practice and policy will depend not only on their statistical significance but also on whether the observed changes in height translate into clinically meaningful benefit. The ability to increase height should not be the sole yardstick for assessing benefit," the editorial states.

"Since growth hormone is well entrenched in the management of Turner's syndrome, the current findings support this aspect of practice but are not likely to change it. Yet the results underscore the need for a measured approach, which includes avoiding unrealistic expectations, when families embark on growth hormone therapy. The early use of low-dose estrogen in conjunction with growth hormone is an interesting possibility. An optimal estrogen-replacement regimen could potentially shorten the period of growth hormone treatment, reduce costs, and improve patient satisfaction. However, implementation would be hampered by the lack of a convenient means to deliver the very small estrogen doses that seem to be optimal for height augmentation."

The authors advise caution when considering supplementing growth hormone treatment with early, low-dose estrogen in Turner's syndrome. "The current results show trends that do not consistently reach significance and show only modest synergy between growth hormone and estrogen in achieving height augmentation, as compared with growth hormone alone. The suggested potential benefits of estrogen on cognition are based on earlier short-term data, and long-term data are needed. We must be concerned about unexpected risks posed by estrogen, being mindful of surprising adverse outcomes of estrogen use in other settings," they write.

According to the National Institutes of Health, Turner syndrome occurs in 1 out of 2,500 female births worldwide and develops when a female (X) sex chromosome is missing in cells or is abnormal. These girls are typically of short stature and have a loss of ovarian function.


'/>"/>

Contact: George Stamatis
george.stamatis@UHhospitals.org
216-844-3667
University Hospitals Case Medical Center
Source:Eurekalert

Related medicine news :

1. Mortality rates are an unreliable metric for assessing hospital quality, study finds
2. Assessing positive outcomes of phase III trials
3. Researchers validate a new test for assessing childrens and teenagers fitness to prevent morbidity
4. Assessing the science behind health claims
5. An appeal to the caregiving values of rural women for breast cancer prevention
6. Mayo Clinic researchers confirm value of therapeutic hypothermia after cardiac arrest
7. Study: Consumers value safer food more than current analyses suggest
8. Supporters and opponents of a special blessing for homosexuals share many values
9. Does Club Drug Ecstasy Have Therapeutic Value?
10. Brief clarifies Social Securitys value for women
11. Biological diversity of ovarian cancer lessens value of screening
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/19/2017)... ... January 19, 2017 , ... ... E-learning system for Clinical and Regulatory education for Physicians, Physician Advisors, Case ... successful education methodology of Disease Specific Documentation Improvement. , The Aerolib Learning ...
(Date:1/19/2017)... ... ... here, many people will have to clear snow with snow blowers or shovels from driveways ... can be dangerous when used incorrectly. That’s why Amica Insurance is sharing the ... blowers:, , When removing wet snow or debris from the blower, ...
(Date:1/19/2017)... ... ... WhoHaha , a digital media company dedicated to creating and delivering female-centric, comedic ... video series that uses humor to highlight ways to improve heart health and overall ... Good™ movement, which is designed to inspire all Americans to make small changes that ...
(Date:1/19/2017)... , ... January 19, 2017 , ... ... a medical capacity this year. Drs. Alexander Paziotopoulos, Andrew Petersen and Trish Henrie-Barrus ... condensed version of the clinic’s leading recovery program. , “We know it’s ...
(Date:1/19/2017)... IL (PRWEB) , ... January 19, 2017 , ... ... N.A., announced it recently provided a new $11,250,000 senior credit facility to Sunrise, ... new MB credit facility were used to facilitate a recapitalization of MedPro led ...
Breaking Medicine News(10 mins):
(Date:1/19/2017)... 19, 2017 Pfizer joins ... Milner Therapeutics Consortium   Major research ... Cambridge   The Milner Therapeutics ... ) as a partner to the Milner Therapeutics Consortium. ... the efficient transfer of materials between industry and academia ...
(Date:1/19/2017)... Marks E-QURE , s 3 ... agreements in Israel and Argentina ... billion global market ... devices for the treatment of advanced wound care, announced today it signed a ... Colombia for the Company,s patented Bio-electrical Signal Therapy device ("BST Device"), ...
(Date:1/19/2017)... 18, 2017   Synthetic Biologics, Inc. ... therapeutics designed to preserve the microbiome to protect ... plans to initiate a Phase 2b/3 adaptive pivotal ... lovastatin lactone designed to reduce methane production by ... gut to treat the underlying cause of irritable ...
Breaking Medicine Technology: